Brokerages Set Astrana Health, Inc. (NASDAQ:ASTH) Price Target at $65.17

Astrana Health, Inc. (NASDAQ:ASTH) has earned an average rating of “Moderate Buy” from the nine analysts that are covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $63.67.

Several research firms have issued reports on ASTH. Macquarie upgraded Astrana Health to a “hold” rating in a research note on Monday, December 16th. Robert W. Baird lifted their target price on Astrana Health from $67.00 to $86.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. TD Cowen began coverage on Astrana Health in a research note on Monday, October 14th. They issued a “buy” rating and a $66.00 target price on the stock. BTIG Research lifted their target price on Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, October 3rd. Finally, Truist Financial cut their target price on Astrana Health from $59.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday.

Institutional Trading of Astrana Health

Large investors have recently made changes to their positions in the company. Janus Henderson Group PLC purchased a new stake in shares of Astrana Health during the third quarter worth approximately $1,164,000. Royce & Associates LP purchased a new stake in shares of Astrana Health during the third quarter worth approximately $6,661,000. Amalgamated Bank purchased a new stake in shares of Astrana Health during the third quarter worth approximately $713,000. Principal Financial Group Inc. purchased a new stake in shares of Astrana Health during the third quarter worth approximately $13,383,000. Finally, Diamond Hill Capital Management Inc. purchased a new stake in shares of Astrana Health during the third quarter worth approximately $8,245,000. 52.77% of the stock is currently owned by hedge funds and other institutional investors.

Astrana Health Stock Performance

Shares of Astrana Health stock opened at $30.28 on Friday. The firm has a market cap of $1.70 billion, a P/E ratio of 23.29, a P/E/G ratio of 1.80 and a beta of 1.20. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60. Astrana Health has a 12 month low of $29.08 and a 12 month high of $63.20. The stock’s fifty day moving average price is $39.55 and its 200-day moving average price is $47.05.

Astrana Health (NASDAQ:ASTH) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.33 EPS for the quarter, meeting the consensus estimate of $0.33. The firm had revenue of $478.71 million for the quarter, compared to analyst estimates of $462.01 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. During the same quarter last year, the firm posted $0.47 earnings per share. On average, equities research analysts expect that Astrana Health will post 1.16 earnings per share for the current fiscal year.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.